A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers

NCT02085473 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma
Healthy Subjects or Volunteers

Interventions

BIOLOGICAL: Tralokinumab 300 mg

Sponsor

MedImmune LLC